Please login to the form below
AirFluSal
This page shows the latest AirFluSal news and features for those working in and with pharma, biotech and healthcare.
Vectura's Flutiform flunks phase III COPD test
But new AirFluSal data demonstrates superior patient adherence over GSK’s Seretide/Advair. ... GSK's product is delivered using its long-established Diskus device, while AirFluSal uses the Vectura-developed Forspiro.
Latest news
-
Teva's Symbicort generic backed for EU approval
The Advair generic, called AirFluSal Forspiro, has since been given a green light in Germany and Sweden.
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- Novacyt launches diagnostic test to differentiate between COVID-19 and flu
- Surviving cancer: a new era for patients
- UK COVID-19 vaccine ‘challenge trials’ could intentionally infect participants with virus
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- BMS eyes approval for second Opdivo combo in kidney cancer
- Live Webinar: Leveraging Digital Technologies to Create Valuable KOL Engagements & Empower Patients
- Live Webinar: Harnessing Technology to Improve Health and Healthcare
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Lilly’s Verzenio scores a win in early-stage breast cancer
- FDA sets January decision date for Xalkori in ALK-positive lymphoma
- Q&A: Isabel Gibson
PMHub
Cuttsy + Cuttsy
How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...
Latest intelligence
- Surviving cancer: a new era for patients
- Now more than ever, a shift in perspective is needed...
- Crisis? No problem!
- Issues planning & management for pharma spokespeople, by Andrew Smith...
- Are patient recruitment and retention rates rising or falling?
- First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Quick links
Infographics
